MagnetisMM-30: A phase 1B, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Lesokhin, A.; Raza, M.; Acosta, J.; Mueller, P. Y.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G. |
| Abstract Title: | MagnetisMM-30: A phase 1B, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM) |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S187 |
| Language: | English |
| ACCESSION: | WOS:001325737900322 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)02162-1 |
| Notes: | Meeting Abstract: P-260 -- Source: Wos |
